Abstract
We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease.
Funder
Indian Council of Medical Research
Cadila Healthcare Limited
Subject
Virology,Infectious Diseases
Reference38 articles.
1. WHO Coronavirus (COVID-19) Dashboardhttps://covid19.who.int/
2. Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Processhttps://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_19August2021.pdf
3. Five reasons why COVID herd immunity is probably impossible
4. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone
5. Use of convalescent plasma therapy in SARS patients in Hong Kong